Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Cancer cell or component thereof
Reexamination Certificate
2011-07-12
2011-07-12
Bristol, Lynn (Department: 1643)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Cancer cell or component thereof
C424S178100, C514S263300, C514S183000, C514S269000
Reexamination Certificate
active
07976852
ABSTRACT:
The invention relates to immunotherapeutic compounds and to methods for stimulating an immune response in a subject individual at risk for developing cancer, diagnosed with a cancer, in treatment for cancer, or in post-therapy recovery from cancer or the compounds of the invention can be administered as a prophylactic to a subject individual to prevent or delay the development of cancer.
REFERENCES:
patent: 5484911 (1996-01-01), Hong et al.
patent: 5635188 (1997-06-01), Bystryn
patent: 5681824 (1997-10-01), Christ et al.
patent: 5895653 (1999-04-01), Eibl et al.
patent: 5904925 (1999-05-01), Exner
patent: 5961970 (1999-10-01), Lowell et al.
patent: 5985284 (1999-11-01), Lowell
patent: 6136797 (2000-10-01), Zilch et al.
patent: 6146632 (2000-11-01), Momin et al.
patent: 6146659 (2000-11-01), Rahman
patent: 6165502 (2000-12-01), Oleske et al.
patent: 6172049 (2001-01-01), Dwyer et al.
patent: 6180111 (2001-01-01), Stein et al.
patent: 6290973 (2001-09-01), Hawkins et al.
patent: 6306404 (2001-10-01), LaPosta et al.
patent: 6355257 (2002-03-01), Johnson et al.
patent: 6437165 (2002-08-01), Mandala et al.
patent: 6521776 (2003-02-01), Hawkins et al.
patent: 6551600 (2003-04-01), Hawkins et al.
patent: 6630161 (2003-10-01), Leesman
patent: 6835721 (2004-12-01), Hawkins et al.
patent: 7416726 (2008-08-01), Ravetch
patent: 7560584 (2009-07-01), Hawkins et al.
patent: 2002/0049314 (2002-04-01), Hawkins et al.
patent: 2002/0176861 (2002-11-01), Hawkins et al.
patent: 2003/0153532 (2003-08-01), Hawkins et al.
patent: 2004/0006242 (2004-01-01), Hawkins et al.
patent: 2005/0123566 (2005-06-01), Hawkins et al.
patent: 2005/0164988 (2005-07-01), Hawkins et al.
patent: 2007/0020232 (2007-01-01), Rossignol et al.
patent: 2007/0027111 (2007-02-01), Hawkins et al.
patent: 2007/0292418 (2007-12-01), Fields et al.
patent: 0 390 216 (1990-03-01), None
patent: 02-261866 (1990-10-01), None
patent: WO 93/04672 (1993-03-01), None
patent: WO 95/11700 (1995-05-01), None
patent: WO 98/57659 (1998-12-01), None
patent: WO 00/44758 (2000-08-01), None
patent: WO 00/73263 (2000-12-01), None
patent: WO 01/46127 (2001-06-01), None
patent: WO 01/90129 (2001-11-01), None
patent: WO 02/09752 (2002-02-01), None
patent: WO 03/003985 (2003-01-01), None
patent: WO 03/011223 (2003-02-01), None
patent: WO 03099195 (2003-12-01), None
Seaver (1994) Genetic Engineering vol. 14(14):pp. 10 and 21.
Chatterjee et al. Cancer Immunol. Imunother. (1994).
Dermer, Biotechnology 12: 320 (1994).
Gura et al (Science 278:1041-1042 (1997).
Voskoglou-Nomikos (Clin. Can. Res. 9:4227-4239 (2003)).
Jain (Scientific American Jul. 1994:58-64).
Esai Research Inst. product datasheet for E6020 or ER-804057 (pp. 1-5; Mar. 1999).
Baselga et al., Cancer Res. 58:2825 (1998).
Cragg et al., Blood 103:2738 (2004).
Overholser et al., Cancer 89:74 (2000).
Clynes et al., Nature Med. 6:443 (2000).
Zhang et al., J. Clin. Oncol. 25:3712 (2007.
Baldridge et al., Exp. Opin. Biol. Ther. 4:1129 (2004).
Jiang et al., Curr. Med. Chem. 10:1423 (2003).
Dalpke et al., Biodrugs 16:419 (2002).
Cooper et al., J. Clin. Immunol. 24:693 (2004).
Skinner, Dermatol. Clint 21:291 (2003).
Coelho et al. (British J. Can. 90:2032-2041 (2004)).
Dennis (Nature 442:739-741 (2006)).
Cespdes et al. (Clin. Transl. Oncol. 8(5):318-329 (2006)).
Talmadge et al. (Am. J. Pathol 170(3):793-804 (2007)).
Fujimori et al. (J. Nuc. Med. 31:1191-1198 (1990)).
Beckman et al. (Can. 109:170-179 (2007)).
Thurber et al. (Adv. Drug Deliv. Rev. 60:1421-1434 (2008)).
Rudnick et al. (Can. Biotherp. & Radiopharm. 24: 155-162 (2009)).
Lederman et al (Molecular Immunology 28:1171-1181, 1991).
Li et al (Proc. Natl. Acad. Sci. USA 77:3211-3214, 1980).
Berenbaum Clin. Exp. Immunol. 28:1-18 (1977).
Berenbaum Pharmacol. Rev. 41:93-141 (1989)).
Tallarida “Drug Synergism and Dose Effect Analysis” Ed. Chapman & Hall (2000), pp. 1-8, 10-13 and 57-71.
Mitchell M S. Immunotherapy as part of combinations for the treatment of cancer. International Immunopharmacology (2003), vol. 3, pp. 1051-1059.
Schuster M et al. Cancer immunotherapy. Biotechnol. J. (2006), vol. 1, pp. 138-147.
Search Report and Written Opinion for PCT/US06/15688, mailed Jul. 31, 2008.
Hawkins LD et al. Inhibition of endotoxin response by synthetic TLR4 antagonists. Current Topics in Medicinal Chemistry (2004), vol. 4, No. 11, pp. 1147-1171.
Hawkins LD et al. A novel class of endotoxin receptor agonists with simplified structure, toll-like receptor 4-dependent immunostimulatory action, and adjuvant activity. The Journal of Pharmacology and Experimental Therapeutics (2002), vol. 300, No. 2, pp. 655-661.
Rossignol DP and Lynn M. TLR4 antagonists for endotoxemia and beyond. Current Opinion in Investigational Drugs (2005), vol. 6, No. 5, pp. 495-502.
Berzoksky and Berkower, “Chapter 8: Immunogenicity and Antigen Structure,”Fundamental Immunology, William E. Paul, ed., Raven Press NY, p. 242 (1993).
Bhattacharya et al., “Synthesis and Vesicle Formation from Novel Pseudoglyceryl Dimeric Lipids. Evidence of Formation of Widely Different Membrane Organizations with Exceptional Thermotropic Properties,”Chem. Commun.23:2287-2288 (1997).
Cespedes of al., “Mouse Models in Oncogenesis and Cancer Therapy,”Clin. Transl. Oncol.8(5):318-329 (2006).
Cheung and Paterson, “American Chemical Society—226thNational Meeting: New Drug Highlights,” IDrugs 6(10):939-942 (2003).
Defoort et al., “Macromolecular Assemblage in the Design of a Synthetic AIDS Vaccine,”Proc. Natl. Acad. Sci. USA89:3879-3883 (1992).
Dennis, “Off by a Whisker,”Cancer News Feature442:739-741 (2006).
Dullenkopf et al, “Synthesis of a Structurally Defined Antigen-Immunostimulant Combination for Use in Cancer Vaccines,”Chem. Euro. J.5(8):2432-2438 (1999).
Duralski et al., “Synthesis of Isotopically Labelled Cardiolipins,”Tetrahedron Lett.1607-1610 (1998).
Eustache et al., “New Acyclic Analogues of Lipid A: Synthesis of 4-Phosphonoxybutyl and 3-Phosphonoxypropyl Glycosides of 2-Amino-2-Deoxy-D-Glucose,”Carbohydrate Res.251:251-267 (1994).
Gokhale et al., “An improved method of encapsulation of doxorubicin in liposomes: pharmacological, toxicological, and therapeutic evaluation,”Br. J. Cancer74:43-48 (1996).
Gregoriadis et al., “Liposomes as Immunological Adjuvants and Vaccine Carriers,”J. Controlled Release41(Jan. 2002):49-56 (1996).
Hawkins et al., “Inhibition of endotoxins response by synthetic TLR4 antagonists,”Curr. Topics Med. Chem.4:1147-71 (2004).
Hoffmann et al., “Induction of Tumor Cytotoxicity in Murine Bone Marrow-Derived Macrophages by Two Synthetic Lipopeptide Analogues,”Biol. Chem.370:575-582 (1989).
Homma et al., “Structural Requirements of Lipid A Responsible for the Functions: A Study with Chemically Synthesized Lipid A and its Analogues,”J. Biochem.98:395-406 (1985).
Inoue and Nojima, “Immunochemical Studies of Phospholipids. I. Reactivity of Various Synthetic Cardiolipin Derivatives with Wassermann Antibody,”Chem. Phys. Lipids1(4):360-367 (1967).
Inoue and Nojima, “Immunochemical Studies of Phospholipids. II, Syntheses of Cardiolipin and its Analogues,”Chem. Pharm. Bull.16(1):76-81 (1968).
Inoue and Nojima, “Immunochemical Studies of Phospholipids IV: The Reactivities of Antisera Against Natural Cardiolipin and Synthetic Cardiolipin Analogues-Containing Antigens,”Chem. Phys. Lipids(CPLIA4) 3(1):70-77 (1969).
Jain et al., “Effect of the Structure of Phospholipid on the Kinetics of Intravesicle Scooting of Phospholipase A2,”Biochimica Biophysica Acta860(3):462-474 (1986).
Jiang and Koganty, “Synthetic Vaccines: The Role of Adjuvants in Immune Targeting,”Curr. Med. Chem.10:1423-1439 (2003).
Kamitakahara et al., “A Lysoganglioside/poly-L-glutamic Acid Conjugate as a Picomolar Inhibitor of Influenza Hemagglutinin,”Angew. Chem. Int. Ed.37(11):1524-1528 (1998).
Lien et al., “A Novel Synt
Fields Scott Z.
Hawkins Lynn D.
Ishizaka Sally T.
Rossignol Daniel P.
Bristol Lynn
EISAI R&D Management Co., Ltd.
Myers Bigel Sibley & Sajovec P.A.
LandOfFree
Compositions and methods for cancer immunotherapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for cancer immunotherapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for cancer immunotherapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2721984